Interstitial Lung Disease News and Research

RSS
Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.
Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Mortality predictors REVEALed for PAH in systemic sclerosis

Mortality predictors REVEALed for PAH in systemic sclerosis

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Chest radiography highly predictive of pulmonary hypertension

Chest radiography highly predictive of pulmonary hypertension

Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

6MWT wording change could enhance serial utility

6MWT wording change could enhance serial utility

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis published in ACR journal

Study confirms exposure to arsenic in drinking water can impair lung function

Study confirms exposure to arsenic in drinking water can impair lung function

ATS releases clinical practice guidelines on management of childhood ILD in infants

ATS releases clinical practice guidelines on management of childhood ILD in infants

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.